Therapeutic brain concentration of the NMDA receptor antagonist amantadine

@article{Kornhuber1995TherapeuticBC,
  title={Therapeutic brain concentration of the NMDA receptor antagonist amantadine},
  author={J. Kornhuber and G. Quack and W. Danysz and K. Jellinger and W. Danielczyk and W. Gsell and P. Riederer},
  journal={Neuropharmacology},
  year={1995},
  volume={34},
  pages={713-721}
}
Amantadine (1-amino-adamantane) is clinically used for the management of Parkinson's disease and drug-induced extrapyramidal symptoms. It has previously been shown that amantadine is a low-affinity uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with rapid blocking and unblocking channel kinetics (Ki-value at the PCP binding site = 10 microM). The aim of the present studies was to estimate concentrations of amantadine in the central nervous system under therapeutic conditions. In… Expand
Persistence of haloperidol in human brain tissue.
Neuroleptic drugs in the human brain
New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET – [11C]raclopride study
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Transport of amantadine and rimantadine through the blood-brain barrier.
  • R. Spector
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental therapeutics
  • 1988
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity
Clinical Pharmacokinetics of Amantadine Hydrochloride
...
1
2
3
4
...